Xilinx Inc. (NASDAQ:XLNX) on 5 March 2015, announced immediate availability of the winter 2015 edition of its award-winning user magazine, Xcell Journal. The cover story for the 90th issue of Xcell Journal takes a system-level look at Xilinx’s newly unveiled UltraScale+™ product portfolio of FPGAs, 3D ICs, and MPSoCs, and how the portfolio yields a 2-5X greater system level performance-per-watt advantage over 28nm devices. On Monday shares of Xilinx Inc. (NASDAQ:XLNX) closed at $40.65. Company’s sales growth for last 5 years was 5.50% and EPS growth for next 5 years is recorded as 7.21%.
Petroleo Brasileiro Petrobras SA (ADR) (NYSE:PBR) will appoint fewer politicians to its board and bring in more professional members who are respected by investors instead, the oil company’s newest director told Reuters on Monday. Petroleo Brasileiro Petrobras SA (ADR) (NYSE:PBR) in last trading activity decreased -6.21% to close at $5.59. Company weekly performance is -12.24% while its quarterly performance stands at -37.26%. Petroleo Brasileiro Petrobras SA (ADR) (NYSE:PBR) is -73.30% away from its 52 week high.
Atossa Genetics, Inc. (NASDAQ:ATOS) announced on 5 March 2015, that management will present at the 27th Annual ROTH Conference on March 11, 2015 at 12:00 pm pacific time at The Ritz Carlton Hotel Laguna Niguel in Dana Point, CA. Management will also be available for one-on-one meetings during the three-day conference. On last trading day Atossa Genetics, Inc. (NASDAQ:ATOS) decreased -1.52% to close at $1.94. Its volatility for the week is 11.50% while volatility for the month is 14.65%. Atossa Genetics, Inc. (NASDAQ:ATOS) monthly performance is 63.03%.
On March 4, the U.S. Federal Communications Commission staff suggested that its $450 million contract with Sterling-based NeuStar, Inc. (NYSE:NSR) be terminated. The recommendation supports Neustar’s rival Ericsson AB subsidiary Telcordia Technologies (ERIC) as the replacement contractor for allowing telephone carriers to route calls and text messages. NeuStar, Inc. (NYSE:NSR) has 1.10% insider ownership. In last trading activity company’s stock closed at $22.25.
Arena Pharmaceuticals (NASDAQ:ARNA) was downgraded by Zacks from a “neutral” rating to an “underperform” rating in a research report issued to clients and investors on Friday. On Monday shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) closed at $4.24. Company’s sales growth for last 5 years was 28.90%.